Clear Cell Ovarian Cancer Patients Lacking ARID1A Protein Could Benefit from ENMD-2076 Treatment, Study Reports

Clear Cell Ovarian Cancer Patients Lacking ARID1A Protein Could Benefit from ENMD-2076 Treatment, Study Reports
Results from a Phase 2 clinical trial indicate that an investigational drug by CASI Pharmaceuticals, known as ENMD-2076, may be beneficial for patients with rare clear cell ovarian cancer (CCOC), particularly those who lack the ARID1A protein, a well-recognized indicator of negative prognosis and a potential biomarker. The findings will be presented at the American Society

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *